Form 4: ZVRA CCO Sells Shares Under 10b5-1 Plan

Zevra Therapeutics' Chief Commercial Officer, Joshua Schafer, sold 10,500 shares of common stock for approximately $96,499.25 under a pre-arranged 10b5-1 plan.

Summary

• Joshua Schafer, Chief Commercial Officer (CCO) of ZEVRA THERAPEUTICS, INC. (ZVRA), reported a sale of common stock.
• The transaction involved the disposition of 10,500 shares of ZVRA common stock.
• The sale occurred on February 3, 2026, at a weighted average price of $9.1905 per share.
• The total value of the shares sold was approximately $96,499.25.
• This transaction was executed pursuant to a Rule 10b5-1(c) plan adopted on March 27, 2025.
• Following this transaction, Joshua Schafer beneficially owns 62,278 shares of ZVRA common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While an insider sale, its execution under a pre-planned 10b5-1 plan mitigates any strong negative sentiment, suggesting personal financial management rather than a reaction to new company-specific information.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are routinely disclosed via Form 4 filings. While a sale can sometimes signal a lack of confidence, transactions executed under a pre-arranged 10b5-1 plan are often for personal financial planning purposes and typically carry less negative signaling compared to open market sales without such a plan. This is a standard disclosure for an executive managing their personal equity holdings.

Stakeholder Impact

• Shareholders: May observe a slight negative sentiment due to an insider sale, though mitigated by the 10b5-1 plan indicating pre-planned personal financial management.

Key Dates

Recommendation

The insider sale was conducted under a pre-arranged 10b5-1 plan, which typically indicates personal financial planning rather than a reaction to new material information. This type of transaction generally does not warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

ZVRA, Zevra Therapeutics, Joshua Schafer, CCO, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Common Stock